Aloe, Flávio, Alves, Rosana S Cardoso, Andrade, Luiz Augusto Franco [UNIFESP], Assis,Márcia, Bacelar, Andrea, Bezerra, Márcio, Cardoso, Francisco [UNIFESP], Ferraz, Henrique Ballalai [UNIFESP], Fonseca, Ronaldo Guimarães, Horta, Wagner, Haddad, Mônica Santoro, Hasan, Rosa, Mattos, James Pitágoras, Prado, Gilmar Fernandes do [UNIFESP], Rizzo, Geraldo, Rodrigues, Nonato, Silva, Ademir Batista da [UNIFESP], Silva, Delson Jose, Teive, Helio Afonso Ghizoni, Grupo Brasileiro de Estudos em Síndrome das Pernas Inquietas (GBE-SPI), Universidade de São Paulo (USP), Hosp Israelita Albert Einstein, Pratica privada, Practica Privada, Universidade Federal de Minas Gerais (UFMG), Universidade Federal de São Paulo (UNIFESP), UFCE, Universidade Federal de Goiás (UFG), Instituto do Cérebro do Hospital Israelita Albert Einstein, Universidade Estadual Paulista (Unesp), Universidade Federal do Ceará (UFC), Universidade de Brasília (UnB), and Universidade Federal do Paraná (UFPR)
Submitted by Vitor Silverio Rodrigues (vitorsrodrigues@reitoria.unesp.br) on 2014-05-27T11:22:34Z No. of bitstreams: 0Bitstream added on 2014-05-27T14:35:05Z : No. of bitstreams: 1 2-s2.0-34548858440.pdf: 168428 bytes, checksum: 7ca90a9cbbebc379300e066e02e2eda9 (MD5) Made available in DSpace on 2014-05-27T11:22:34Z (GMT). No. of bitstreams: 0 Previous issue date: 2007-09-01 This article contains the conclusions of the November 17-18, 2006 meeting of the Brazilian Study Group of Restless Legs Syndrome (GBE-SPI) about diagnosis and management of restless legs syndrome (RLS). RLS is characterized by abnormal sensations mostly but not exclusively in the legs which worsen in the evening and are improved by motion of the affected body part. Its diagnosis is solely based on clinical findings. Therapeutic agents with efficacy supported by Class I studies are dopamine agonists, levodopa and gabapentine. Class II studies support the use of slow release valproic acid, clonazepan and oxycodone. The GBE-SPI recommendations for management of SPI are sleep hygiene, withdrawal of medications capable of worsening the condition, treatment of comorbidities and pharmacological agents. The first choice agents are dopaminergic drugs, second choice are gabapentine or oxycodone, and the third choice are clonazepan or slow release valproic acid. Departamento de Neurologia Hospital Das Clínicas USP-SP Serviço de Neurologia Infantil Departamento de Neurologia USP-SP Instituto do Cérebro do Hospital Israelita Albert Einstein, São Paulo Departamento de Clínica Médica Setor de Neurologia Universidade Federal de Minas Gerais Departamento de Neurologia Escola Paulista de Medicina UNIFESP Departamento de Neurologia UNESP, Botucatu-SP Setor de Neurologia UFCE Departamento de Neurologia UNB Serviço de Neurologia Hospital Das Clínicas UFG Departamento de Clínica Médica Setor de Neurologia UFPR , Avenida Pasteur 89 / 1107, 30150-290 Belo Horizonte MG Departamento de Neurologia UNESP, Botucatu-SP